European Innovation Council

ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successful development of our products.

neuroClues provides easy-to-use eye-tracking environment to help practitioners instantaneously quantify their clinical exam.

timeisbrain is a medical device for improving the diagnostics and prognostics of acute ischaemic stroke

Legacy Healthcare is developping safer drugs for the treatment of autoimmune and inflammatory diseases in fragile patients

Ariadne.ai ag is a contract research organization (CRO) that specializes in automated high-throughput biomedical image analysis and image processing technology. The company offers a scalable and consistent solution to image processing and analysis bottlenecks, allowing R&D teams to concentrate on staining and imaging. Whether customers need to automate an existing workflow or create a new one, Ariadne.ai ag is ready to help, allowing them to scale their experiments.

TILT Biotherapeutics is the leading company globally working in the area of enabling tumor T-cell therapy with oncolytic viruses. TILT is a preclinical stage company working in the field of cancer immunotherapy and will soon translate its unique approach into clinical trials. The company’s patented technology involves utilization of oncolytic viruses for enhancement of tumor T-cell therapy. Initial embodiments of the technology will be used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR-T) and checkpoint inhibiting antibody therapy. The TILT approach has the potential to achieve similar results in CAR-T therapy of solid tumors as currently achieved for CD19+ hematological tumors.

Perha Pharmaceuticals is a biotechnology company that specializes in the research and development of kinase inhibitors. The company's investigation begins with natural marine substances. Indeed, some of the molecules optimized by Perha Pharmaceuticals' chemists and biologists are derived from natural products isolated from marine organisms.

VBL Therapeutics is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel treatments for cancer and immune-inflammatory diseases. VBL’s clinical pipeline is based on two distinct, proprietary platform technologies that leverage the body’s natural physiologic and genetic regulatory elements.

CRIAM offers rapid and accurate blood typing and infectious diseases detection anywhere, enabling prompt and well-informed clinical decision-making. Our stand-alone platform is portable and does not require electricity nor additional equipment or laboratory infrastructure, ensuring accessibility and usability in diverse settings. In addition, our solution is highly scalable: one reader can perform several types of tests using specific cartridges and computer vision algorithms suitable for detecting a wide range of infectious diseases, thus consolidating market penetration.

Sequentia Biotech was founded in 2013 by Walter Sanseverino (CEO) and Riccardo Aiese Cigliano (CSO), two young researchers with a real passion for genetics and omics sciences, and is based at the UAB Research Park. Sequentia is a bioinformatics company that offers services and tools that transform genomic data into knowledge in academic research, plant and animal breeding and biomedicine. In just four years, Sequentia has achieved a large highly diversified portfolio of clients and partners, consisting of over 30 public and private research centers, companies and hospitals. The company is taking part in more than 160 R & D public and private projects, and it has two open source biodata banks; and an award-winning R&D line, Tricopharming, which was established in 2014. Cofounders Walter Sanseverino and Riccardo Aiese have published more than 40 scientific articles in high impact journals such as Nature Genetics, Scientific Report or DNA Research.

Sequentia Biotech was founded in 2013 by Walter Sanseverino (CEO) and Riccardo Aiese Cigliano (CSO), two young researchers with a real passion for genetics and omics sciences, and is based at the UAB Research Park. Sequentia is a bioinformatics company that offers services and tools that transform genomic data into knowledge in academic research, plant and animal breeding and biomedicine. In just four years, Sequentia has achieved a large highly diversified portfolio of clients and partners, consisting of over 30 public and private research centers, companies and hospitals. The company is taking part in more than 160 R & D public and private projects, and it has two open source biodata banks; and an award-winning R&D line, Tricopharming, which was established in 2014. Cofounders Walter Sanseverino and Riccardo Aiese have published more than 40 scientific articles in high impact journals such as Nature Genetics, Scientific Report or DNA Research.

RemedyBio is an immunology-focused discovery and development company based in Dublin, Ireland. It has pioneered a new approach to understanding the immune system and the discovery of new therapies.

Xenothera is a xenotherapy platform with embedded technology that renovates immunological treatments. Xenothera creates new therapeutic modes in numerous domains from immunomodulation to infectious diseases. Xenothera's technological platform is built on a double expertise of animal genetics and mastery of immunology processes. It renovates passive immunotherapy by marketing a new generation of hyperimmune polyclonal sera. Xenothera’s platform ensures short-time development thanks to their mastery of the entire process, from animal genetics, choice of the immunogen, selection, and purification of interesting immunoglobulins, and access to market authorization in accelerated timescale.

Developer of microbiome analysis technology designed to monitor the microbiome status and function and quantify its impact on all aspects of human life. The company's technology simplifies, accelerates, and democratizes microbiome analysis to precisely measure the composition and dynamics of the microbiome by uncovering its role in human health and the environment, enabling researchers to access genetic analysis devices to analyze the full genetic makeup of microbiomes.

PROSION Therapeutics is a drug development company with a proprietary platform to adress unmet medical needs (e.g. cancer, diabetes) by unlocking undruggables

Developer of microbiome analysis technology designed to monitor the microbiome status and function and quantify its impact on all aspects of human life. The company's technology simplifies, accelerates, and democratizes microbiome analysis to precisely measure the composition and dynamics of the microbiome by uncovering its role in human health and the environment, enabling researchers to access genetic analysis devices to analyze the full genetic makeup of microbiomes.

At Quantib we come to work every day to help physicians solve the hardest challenges they face when diagnosing patients. Our smart software analyzes medical images to unravel secrets hidden to the naked eye. Are you excited to learn more about how artificial intelligence techniques can move healthcare forward and help our marketing department tell this story to the world? We’d love for you to join our tight team of 22 conquering the medical world with deep learning software.

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy.

RemedyBio is an immunology-focused discovery and development company based in Dublin, Ireland. It has pioneered a new approach to understanding the immune system and the discovery of new therapies.

Xenothera is a xenotherapy platform with embedded technology that renovates immunological treatments. Xenothera creates new therapeutic modes in numerous domains from immunomodulation to infectious diseases. Xenothera's technological platform is built on a double expertise of animal genetics and mastery of immunology processes. It renovates passive immunotherapy by marketing a new generation of hyperimmune polyclonal sera. Xenothera’s platform ensures short-time development thanks to their mastery of the entire process, from animal genetics, choice of the immunogen, selection, and purification of interesting immunoglobulins, and access to market authorization in accelerated timescale.

ADmit Therapeutics is a biotechnology company that specializes in the development of early Alzheimer's disease diagnosis tests. The company's test is based on an epigenetic analysis in blood samples, covering the analysis of a large number of methylcytosines in mtDNA by next-generation sequencing, enabling medical practitioners with an easy way to detect early-stage Alzheimer.

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy.

EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware and software components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.

MeMed Diagnostics is a personalized diagnostics company founded in 2009. They are here to improve patient care, empower physicians, and lower health-care costs through rapid and actionable diagnostics for infectious diseases. Their main focus is preventing antibiotics misuse. Antibiotics are the most prescribed class of drugs worldwide with a global market of 25-30 billion $US. Up to 70% of antibiotics are estimated to be prescribed inappropriately, making them the most misused drug class in the world. Antibiotics misuse leads to ineffective treatment, emergence of resistant strains of bacteria, and is estimated to cost healthcare systems worldwide tens of billions of dollars annually. Their platform, the ImmunoDx™, leverages the world’s most accurate diagnostic system for differentiating bacteria from viruses, crafted by nature, the body’s immune system. ImmunoDx™ combines proprietary biomarkers, algorithms, and clinical know-how to identify the source of infection (virus vs bacteria, bacterial spectrum), by decoding the immune system`s differential response to different pathogens. This unique approach enables ImmunoDx™ to address some of the major challenges facing currently available diagnostics for infectious diseases.

S-Biomedic brings novel therapeutic solutions to the skin microbiome.The skin microbiome - a habitat of billions of beneficial and harmful bacteria - contributes to healthy skin. An imbalance of these bacteria can lead to a variety of skin conditions including acne, eczema, rosacea and ageing. S-Biomedic uses a targeted modulation-based technology to modify the skin microbiome. This technology can be applied in both the dermatology and cosmetic industries. They design their products using the latest advances in microbiology and dermatology. Using their technology, beneficial bacteria are selected and combined to generate products that accelerate the rebalancing of a disease microbiome. In this way, they are able to restore a healthy state back to your skin.

Medicortex Finland is developing the first, non-invasive, point-of-care diagnostic test for Traumatic Brain Injury and concussion. Problem: A Traumatic Brain Injury (TBI) happens when an external force to the head causes damage to the brain tissue. Mild TBI, which is also known as concussion, is difficult to diagnose with current diagnostic methods such as CT and MRI scans. Solution: Medicortex is working towards the incorporation of brain injury biomarkers into a hand-held diagnostic kit, which will give a reliable result rapidly and will not require medical professionals to interpret the result. Business: We identified a unique biomarker that can be detected from urine and saliva. With strong clinical evidence and protected idea, we are willing to negotiate with bigger diagnostic companies for collaboration on manufacturing and distribution. Market: Customers include hospitals, emergency rooms, paramedics and first responders, military paramedics, sports teams (especially contact sports such as rugby, American football, ice hockey), schools, pharma and insurance companies. Accomplishments: We have completed three clinical trials which have demonstrated the ability of the proprietary biomarker to distinguish TBI patients from healthy controls. The company has received grant funding from US Department of Defense (twice), European Union and Finnish Government.